Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial
- PMID: 15554568
- DOI: 10.1017/s0033291703001776
Efficacy and safety of methylphenidate in 45 adults with attention-deficit/hyperactivity disorder. A randomized placebo-controlled double-blind cross-over trial
Abstract
Background: Data on the efficacy and safety of methylphenidate in adults with attention deficit/ hyperactivity disorder (ADHD) are lacking in Europe. This study was undertaken to report on the efficacy and safety of methylphenidate in an adult out-patient population with ADHD, and to compare results with US data.
Method: A double-blind randomized cross-over trial comparing methylphenidate and placebo in 45 adults with ADHD with childhood onset was performed in a dose-titration design. Methylphenidate was titrated from 0.5 mg/kg per day in week 1 up to 1.0 mg/kg per day in week 3.
Results: Response rates using methylphenidate varied between 38 and 51%, and using placebo between 7 and 18% (p<0.05), depending on outcome measure used. Although the overall percentage of subjects having any side effect on both methylphenidate and placebo was rather high, side effects on methylphenidate over and above those on placebo were few and mild.
Conclusions: Methylphenidate proves to be an effective and well tolerated treatment for symptoms of ADHD in adults in the short term. Future research should study the long-term response and clarify the impact of gender, co-morbidity, socio-economic status and IQ on response rates in adults with ADHD.
Similar articles
-
A randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of osmotic-controlled release oral delivery system methylphenidate HCl in adults with attention-deficit/hyperactivity disorder in Japan.World J Biol Psychiatry. 2014 Aug;15(6):488-98. doi: 10.3109/15622975.2013.868925. Epub 2014 Jan 23. World J Biol Psychiatry. 2014. PMID: 24456065 Clinical Trial.
-
Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study.J Clin Psychopharmacol. 2009 Jun;29(3):239-47. doi: 10.1097/JCP.0b013e3181a390ce. J Clin Psychopharmacol. 2009. PMID: 19440077 Clinical Trial.
-
OROS-methylphenidate efficacy on specific executive functioning deficits in adults with ADHD: a randomized, placebo-controlled cross-over study.Eur Neuropsychopharmacol. 2014 Apr;24(4):519-28. doi: 10.1016/j.euroneuro.2014.01.007. Epub 2014 Jan 18. Eur Neuropsychopharmacol. 2014. PMID: 24508533 Clinical Trial.
-
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2014 Sep 18;(9):CD005041. doi: 10.1002/14651858.CD005041.pub2. Cochrane Database Syst Rev. 2014. Update in: Cochrane Database Syst Rev. 2016 May 26;(5):CD005041. doi: 10.1002/14651858.CD005041.pub3 PMID: 25230710 Updated. Review.
-
[Efficacy and safety of stimulants and non-stimulants in adults with attention deficit hyperactivity disorder (ADHD)].Harefuah. 2011 Oct;150(10):788-90, 814. Harefuah. 2011. PMID: 22111124 Review. Hebrew.
Cited by
-
Effects of prolonged methylphenidate treatment on amygdala reactivity and connectivity: a randomized controlled trial in stimulant treatment-naive, male participants with ADHD.Psychoradiology. 2021 Oct 22;1(3):152-163. doi: 10.1093/psyrad/kkab013. eCollection 2021 Sep. Psychoradiology. 2021. PMID: 38665807 Free PMC article.
-
Neural and Cognitive Predictors of Stimulant Treatment Efficacy in Medication-Naïve ADHD Adults: A Pilot Diffusion Tensor Imaging Study.J Atten Disord. 2024 Mar;28(5):936-944. doi: 10.1177/10870547231222261. Epub 2024 Feb 7. J Atten Disord. 2024. PMID: 38321936 Free PMC article.
-
The risk of eating disorders among children and adolescents with attention deficit hyperactivity disorder: Results of a matched cohort study.Int J Pediatr Adolesc Med. 2021 Jun;8(2):102-106. doi: 10.1016/j.ijpam.2020.06.002. Epub 2020 Jul 6. Int J Pediatr Adolesc Med. 2021. PMID: 34084881 Free PMC article.
-
Effect of a Multi-Layer, Extended-Release Methylphenidate Formulation (PRC-063) on Sleep in Adults with ADHD: A Randomized, Double-Blind, Forced-Dose, Placebo-Controlled Trial Followed by a 6-month Open-Label Extension.CNS Drugs. 2021 Jun;35(6):667-679. doi: 10.1007/s40263-021-00814-z. Epub 2021 May 31. CNS Drugs. 2021. PMID: 34057707 Free PMC article. Clinical Trial.
-
Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults.Cochrane Database Syst Rev. 2021 Jan 18;1(1):CD013011. doi: 10.1002/14651858.CD013011.pub2. Cochrane Database Syst Rev. 2021. PMID: 33460048 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical